DoD Prostate Cancer, Clinical Consortium Award
ID: 359060Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359060
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2025 Prostate Cancer Research Program Clinical Consortium Award, aimed at advancing clinical trials for novel therapeutic interventions in prostate cancer. This grant supports the establishment of a consortium of leading researchers across multiple institutions to expedite the clinical advancement of treatments, with a focus on understanding disease progression, improving patient quality of life, and ensuring equitable access to care for high-risk populations. The total estimated funding for this opportunity is approximately $36.8 million, with $12.2 million allocated for one Coordinating Center and $24.6 million for up to eleven clinical research sites, each with specific funding caps and a duration of four years. Interested applicants must submit a pre-application by August 8, 2025, followed by a full application by August 29, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942525PCRPCCA_GG.pdf
    The Department of Defense's Defense Health Program has announced the Fiscal Year 2025 Prostate Cancer Research Program Clinical Consortium Award (Funding Opportunity Number HT942525PCRPCCA). The program aims to advance clinical trials targeting novel therapeutic interventions for prostate cancer and to foster collaboration among leading researchers across multiple organizations to expedite patient treatment. This opportunity allocates approximately $12.2 million for one Coordinating Center and $24.6 million for up to eleven clinical research sites, each with specific cost caps and funding duration of four years. Eligible applicants include extramural and intramural organizations, ranging from academic institutions to biotech firms, with principal investigator requirements. The application process involves a two-step submission: a pre-application by August 8, 2025, and a full application by August 29, 2025. Each proposal must align with overarching challenges such as understanding prostate cancer progression, developing new treatments, improving quality of life, and ensuring equitable access to care, particularly for high-risk populations. The program emphasizes creating a consortium to effectively manage clinical trials, requiring adherence to rigorous research and regulatory standards, with expectations for sustained financial viability post-award. This initiative underscores the DOD's commitment to tackling prostate cancer, benefiting service members, veterans, and the broader community impacted by the disease.
    Similar Opportunities
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Metastasis Research Network (U54 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Metastasis Research Network (U54 Clinical Trial Not Allowed), aimed at advancing research on cancer metastasis through the establishment of specialized centers. Applicants are required to propose a cohesive scientific theme supported by two or three interdisciplinary research projects that utilize integrative system-level approaches to understand the complexities of metastasis, including factors such as early dissemination and cellular responses to therapies. This initiative is crucial for enhancing our understanding of metastasis as a systemic issue across various cancer types, including rare and pediatric cancers. The total estimated funding for this program is $6.8 million, with individual awards capped at $1.7 million, and the application deadline is expected to close on May 15, 2026. For further inquiries, interested parties can contact Joanna M. Watson, Ph.D., at 240-276-6206 or via email at watsonjo@mail.nih.gov.
    Staff Research Program
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity for the Staff Research Program, aimed at engaging scientific staff in collaborative research with higher education institutions. This program seeks to enhance the professional competence of Army Research Office (ARO) scientists through hands-on, fundamental research in various scientific fields, including engineering, physical sciences, and life sciences, with a focus on advancing knowledge relevant to Army missions. Eligible applicants include institutions recognized for their scientific research capabilities, and the funding will be provided through cooperative agreements with award amounts ranging from $200,000 to $10 million. Proposals must be submitted via Grants.gov by June 2, 2030, and interested parties can contact Mr. William Creech at William.a.creech3.civ@army.mil for further information.
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)." This initiative aims to foster interdisciplinary research teams that can translate scientific discoveries into practical tools and methods for diagnosing and treating diseases, addressing both clinical and non-clinical challenges. The program is particularly significant for enhancing cancer research and improving patient care outcomes, with a maximum funding amount of $499,000 per year available for projects lasting up to five years. Applications will be accepted starting January 5, 2025, with a closing date of January 8, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html.
    Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Human Cancers, specifically for the fiscal years 2027, 2028, and 2029, under the P50 Clinical Trial Required grant program. This initiative aims to fund innovative translational research that enhances prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups, utilizing advanced cellular, molecular, and genetic approaches. With an estimated total program funding of $25 million and the expectation of awarding 12 grants, interested applicants must submit their proposals by January 25, 2027, with the anticipated award date set for June 4, 2027. For further inquiries, applicants can contact Bradley T. Scroggins at bradley.scroggins@nih.gov or by phone at 240-276-7860.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network, specifically targeting Network Lead Academic Participating Sites through a cooperative agreement. The primary objective is to provide scientific leadership in developing and conducting multi-center clinical trials for various cancer treatments, contributing to substantial patient accrual across the NCTN. This initiative is crucial for advancing clinical research and improving treatment options for diverse patient populations affected by cancer. The estimated total program funding is $35,100,000, with an award ceiling of $1,700,000 and approximately 35 awards expected. Interested applicants should prepare for the anticipated application due date in late February 2025, following the NOFO publication in Fall 2024.
    Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)" aimed at fostering long-term partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs). This initiative seeks to enhance cancer research by addressing disparities in cancer outcomes and promoting outreach and engagement across diverse populations. The program anticipates awarding approximately 12 cooperative agreements, with a minimum funding amount of $850,000, and key deadlines include an estimated synopsis close date of January 16, 2026, and an expected award date of September 1, 2026. For further inquiries, interested applicants can contact Dr. Sandra San Miguel-Majors at 240-276-5977 or via email at ncicpachU54@mail.nih.gov.
    George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional), aimed at fostering impactful, multi-disciplinary research in urology through diverse collaborations. This program seeks to continue the support for the NIDDK George M. O’Brien Urology Cooperative Research Centers, which serve as a national resource for the urology research community. With an estimated total program funding of $5.3 million and the expectation of awarding five grants, interested applicants, including Indian/Native American Tribal Governments, eligible federal agencies, and non-domestic entities, should note that the application period will open with a synopsis posted on April 1, 2026, and close on July 1, 2026. For further inquiries, applicants can contact Deepak Nihalani at deepak.nihalani@nih.gov or by phone at 301.594.6417.